Shoshanna Solomon is The Times of Israel s Startups and Business reporter
A 3D illustrative image of rod-shaped bacteria and cocci in the human microbiome (Dr Microbe; iStock by Getty Images)
MyBiotics Pharma Ltd. said Tuesday it will work with Hadasit Medical Research Services and Development Ltd., the technology transfer arm of Hadassah Medical Center, to identify microbiome-based therapies to improve the impact of cancer immunotherapies in melanoma patients.
MyBiotics has developed technologies to culture, ferment and deliver highly stable and diverse bacterial communities that can target different sites across the human body to restore the microbiome equilibrium.
The collaboration will combine Hadassah’s knowhow and expertise in immunotherapy treatment for melanoma patients with MyBiotics’ microbiome technologies to enable development of new drugs, the companies said in a statement.
Israel
Michal-lotem
Kfir-umansky
David-daboush
Mybiotics-pharma
Hadasit-medical-research-services
Hadassah-medical-center
Development-ltd
Mybiotics-pharma-ltd
Hadassah-cancer-research-institute
Department-of-oncology-at-hadassah-medical-center
Hadassah-medical
Antibiotic-free remedy aims to conquer bacterial vaginosis
Ferring, Rebiotix and MyBiotics collaborate to develop live microbiome-based biotherapeutics in reproductive medicine and maternal health.
Illustrative photo by Imani Bahati on Unsplash
A live biotherapeutic remedy based on a woman’s female microbiome is under development to treat bacterial vaginosis. This common infection among women of reproductive age is linked to increased risk of miscarriage and complications to pregnancy and fertility.
The treatment is being developed in a partnership among Ferring Pharmaceuticals of Switzerland, Ferring subsidiary Rebiotix of Minnesota, and MyBiotics Pharma of Rehovot, Israel.
Currently, bacterial vaginosis is treated with antibiotics, which can disrupt the vaginal microbiome and does not prevent the infection from reoccurring. The aim of a microbiota-based treatment would be to reduce antibiotic use and provide a long-term treatment solution.
Minnesota
United-states
Israel
Switzerland
Rehovot
Hamerkaz
Israeli
David-daboush
Mybiotics-pharma
Mybiotic-mycrobe
Ferring-pharmaceuticals-of-switzerland
Ferring-pharmaceuticals